Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Xenothera SAS
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
I1) Male or female patient aged 18 years or over, weighing \>50 Kg and \<120 Kg, at the time of signing the informed consent,
I2) Patient presenting in a specialized or an emergency unit
I3) Patient presenting signs of pneumonia evidenced by at least 1 of the following: auscultation, chest X-Ray, CT scan OR presenting COVID-19 related symptoms having started less than 10 days prior to screening visit, including at least 2 of the following: fever, cough, sore throat or nasal discharge, dyspnea (shortness of breath), thoracic pain, headache or fatigue, myalgia, anosmia, dysgeusia, diarrhea, nausea
I4) Patient with SpO2 \> 90% (at ambient air)
I5) Patient with a first positive SARS-CoV-2 test (RT-PCR, RT-qPCR or antigen test) in the last 10 days or at screening
I6) Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at screening and use a highly effective birth control until 90 days after the administration of study drug
I7) Non-vasectomized male patients having a female partner of childbearing potential must agree to use a highly effective method of contraception until 90 days after the administration of study drug,
I8) Patient capable of giving signed informed consent.
You may not be if
E1) Patient with a positive SARS CoV-2 test (RT-PCR, RT-qPCR or antigen test) of more than 10 days before the screening visit
E2) Patient with multiorgan failure
E3) Patient requiring immediate Intensive Care Unit (ICU) hospitalization
E4) Patient participating in another clinical trial with an investigative agent
